Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2019-03-20 Audit Report / Informat…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
CELON_RAPORT_Y2018_Funkcjionowanie_komitetu_audytu.pdf
Audit Report / Information Classification · 95% confidence The document is a formal declaration ('Oświadczenie') from the Supervisory Board ('Rada Nadzorcza') of Celon Pharma S.A. specifically concerning the functioning of the Audit Committee ('Komitet Audytu') for the fiscal year 2018. This content directly relates to the internal rules, board structure, and governance practices of the company, particularly regarding its oversight functions. This aligns best with the Governance Information category (CGR), which covers internal rules and board structure, rather than a standalone Audit Report (AR) or a general management report (MDA). The document is short and appears to be a specific governance disclosure. FY 2018
2019-03-20 Polish
CELON_RAPORT_Y2018_Informacja_Zarzadu_nt_firmy_audutorskiej.pdf
Regulatory Filings Classification · 99% confidence The document is titled "Informacja Zarządu Celon Pharma S.A. w sprawie wyboru firmy audytorskiej" (Information of the Management Board of Celon Pharma S.A. regarding the selection of the audit firm). It explicitly discusses the selection process, independence, rotation, and related policies concerning the auditor for the financial statement audit for the fiscal year 2018. This content directly relates to the formal audit process and associated governance/reporting requirements, but it is not the full Audit Report itself (AR) nor the Annual Report (10-K). It is an official announcement/information regarding the audit firm selection, which falls under the scope of Audit Report / Information (AR) as defined, especially since it details compliance with audit standards and rotation rules, which are core components of audit oversight.
2019-03-20 Polish
CELON_RAPORT_Y2018_rzetelnosc_sprawozdan.pdf
Management Reports Classification · 99% confidence The document is a formal declaration ('Oświadczenie Zarządu') by the Management Board of Celon Pharma S.A. regarding the fairness and accuracy of their annual financial statements ('roczne sprawozdanie finansowe') and the Management Board's report for the fiscal year 2018. This type of statement, confirming the adherence to accounting principles and the true representation of financial status, is a standard component often found within or accompanying the full Annual Report (10-K) or a standalone Audit Report (AR). Given the content focuses specifically on the veracity of the annual financial reporting and management report for the full year 2018, it aligns most closely with the scope of an Audit Report/Information (AR), which covers applied accounting principles and results related to financial statements, even if it's a management assertion rather than the auditor's opinion itself. It is too specific for a general Regulatory Filing (RNS) and is not an announcement of a report (RPA) but the content of a required declaration.
2019-03-20 Polish
Sprawozdanie_z_badania_-_Celon_Pharma_2018_signedWM.pdf
Audit Report / Information Classification · 99% confidence The document is titled "Sprawozdanie niezależnego biegłego rewidenta z badania" (Independent Auditor's Report on the Audit) and contains sections like "Nasza opinia" (Our opinion), "Podstawa opinii" (Basis for opinion), and details about the audit scope, materiality thresholds, and key audit matters (like capitalization of development costs and accounting for subsidies). This structure is characteristic of a formal audit report accompanying financial statements. The definition for Audit Report / Information (AR) states: "Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports).". Since this is clearly an auditor's opinion on the financial statements, AR is the most appropriate classification, distinguishing it from the full 10-K Annual Report. FY 2018
2019-03-20 Polish
Uzyskanie patentu w zakresie inhibitorów fosfodiesterazy 10A (PDE10A) w Chinach - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short announcement (1229 characters) from Celon Pharma S.A. regarding obtaining a patent for PDE10A inhibitors in China from the CNIPA. It details the significance of the patent for commercialization and mentions ongoing clinical trials (Project NoteSzHD). Since this is a specific, material announcement concerning intellectual property and regulatory milestones, it fits best under the general category for regulatory announcements that are not specifically earnings, director dealings, or capital changes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, non-standard regulatory update that doesn't fit the other defined categories like LTR (Legal Proceedings) or CAP (Financing). It is not an Earnings Release (ER), Interim Report (IR), or a Report Publication Announcement (RPA) as it is the primary disclosure of the event, not an announcement *about* another report.
2019-03-08 Polish
Zarekomendowanie przez NCBiR wniosków o dofinansowanie dwóch projektów Spółki - Content (PL)
Capital/Financing Update Classification · 98% confidence The document is a formal announcement by the management board ('Zarząd') of Celon Pharma S.A. regarding the approval of funding for two specific R&D projects by the National Centre for Research and Development (NCBiR). It details the project scope, costs, and potential funding amounts, concluding with a statement that final funding amounts may change and that the company will report separately upon signing the funding agreements. This content relates directly to the company's financing activities, specifically securing grants/subsidies for capital projects (R&D). This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2019-01-31 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.